Novo Nordisk drug trials show benefits for weight loss and blood sugar reduction
Danish pharmaceutical company Novo Nordisk (NVO.US) announced that a mid-stage clinical trial of an experimental drug named Amycretin conducted in patients with type 2 diabetes has yielded positive results, showing significant reductions in both weight and blood sugar levels.
The company noted that the weight loss drug candidate has shown effectiveness in both pill and injection forms. The news propelled the company's stock price to rise over 3% in the U.S. market
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments